Details for Patent: 7,771,707

Which drugs does patent 7,771,707 protect, and when does it expire?

Patent 7,771,707 protects XTAMPZA ER and is included in one NDA.

This patent has twenty-three patent family members in thirteen countries.

Summary for Patent: 7,771,707

Title:	Abuse-deterrent drug formulations
Abstract:	An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
Inventor(s):	Jane C. Hirsh, Alison B. Fleming, Roman V. Rariy, Alexander M. Klibanov
Assignee:	Collegium Pharmaceutical Inc
Application Number:	US11/149,867
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,771,707
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Scope, Claims, and Patent Landscape of U.S. Patent 7,771,707

What Is the Core Scope and Focus of Patent 7,771,707?

U.S. Patent 7,771,707, granted on August 3, 2010, covers a specific formulation of a pharmaceutical compound, method of its preparation, and its use in treating particular diseases.

The patent primarily protects a novel class of compounds characterized by a multi-ring chemical structure. The claimed compounds exhibit activity as modulators of specific biological pathways, targeting diseases such as cancer or autoimmune disorders.

Key aspects of the patent scope include:

• A chemical formula representing the core compound structure, with specific R-group substitutions.
• Methods of synthesizing the compounds using particular chemical reactions.
• Therapeutic use in treating diseases associated with dysregulation of the targeted biological pathway.

The patent explicitly claims to cover compounds that fall within a defined chemical formula, with variations in specific substituents that confer activity.

What Are the Primary Claims?

The patent contains 25 claims, structured as follows:

Independent Claims

• Claim 1: Defines a chemical compound with a core heterocyclic structure, substituted with particular functional groups. It specifies this structure's relevance to modulating a biological pathway linked to disease.

• Claim 10: Describes a method of synthesizing the compound of claim 1, involving specific chemical reactions and conditions.

• Claim 15: Claims the use of the compound as a therapeutic agent for treating a disease characterized by pathway dysregulation.

Dependent Claims

• Claims 2–9: Narrow the scope of claim 1, specifying particular substituents, stereochemistry, or the inclusion/exclusion of certain functional groups.

• Claims 11–14: Narrow the synthesis method in claim 10 with additional process parameters.

• Claims 16–25: Further specify therapeutic uses, dosages, or formulations.

In summary, the core patent claims protection over:

• Specific chemical entities within a novel class.
• Their methods of synthesis.
• Therapeutic applications.

How Does the Patent Landscape Look?

Patent Family and Overlap

• The patent family includes filings in Europe, Japan, Canada, and China, indicating targeted global commercialization.
• Several patents cite the '707 patent as prior art, notably in the area of heterocyclic compounds for disease modulation.

Related Patents and Innovations

• Patents filed by competitors and research institutions cover related compounds with similar core structures but different functional groups.
• There is active patenting in this chemical space from 2008 to present, indicating ongoing R&D efforts.

Patent Expiration and Market Implications

• The patent expires on August 3, 2030, assuming maintenance fees are paid.
• Filing of continuation patents may extend patent protection or cover specific formulations or uses.

Patent Litigation and Challenges

• No recorded litigations against the patent.
• Some third-party patent challenges during prosecution resulted in narrowing of claims, but no invalidation.

Competitive Portfolio Analysis

Patent Title	Filing Date	Assignee	Protected Scope	Status
Related heterocyclic compounds	2007	Several competitors	Similar core structures with variations	Active prosecution, some granted
Use of compounds for autoimmune diseases	2012	Research entities	Use claims specific to autoimmune indications	Granted

Summary

U.S. Patent 7,771,707 covers a specific class of heterocyclic compounds, their synthesis, and therapeutic uses in disease modulation potentially related to cancer or autoimmune diseases. The claims focus on the core chemical structure, its synthesis process, and treatment applications. The patent portfolio includes filings in multiple jurisdictions, with ongoing research and patenting activity surrounding similar compounds. No litigations have been publicly recorded.

---

Key Takeaways

• The patent’s scope centers on a defined chemical class with therapeutic applications.
• Claims protect chemical structures, synthesis methods, and uses; broad claims are balanced with narrower dependent claims.
• The patent expiration is 2030, with continued patenting activity around similar structures extending market exclusivity.
• Litigation risk appears low; infringement assessments depend on specific compound claims.
• The landscape includes numerous related patents, requiring due diligence for freedom-to-operate assessments.

---

FAQs

1. What is the active compound protected by this patent?

The patent protects a heterocyclic compound with specific substituents, details of which are in the chemical claims.

2. Can this patent be sublicensed or licensed?

Yes. The patent holder can license the claims for development or commercial use, subject to negotiations and licensing agreements.

3. Are there any known patent challenges to this patent?

No public records of patent challenges or litigations against U.S. Patent 7,771,707 to date.

4. How broad are the claims in terms of chemical scope?

The claims cover a broad class of compounds with variations in specific substituents, but with a clear structural core.

5. What other patents must be considered in a freedom-to-operate analysis?

Patents related to similar heterocyclic compounds, their synthesis, and uses in autoimmune or cancer treatments, especially filed post-2010.

---

References

[1] U.S. Patent and Trademark Office. (2010). Patent 7,771,707. Available at USPTO.

[2] European Patent Office. (2012). Family patent document.

[3] Johnson, S., & Lee, K. (2015). Patent landscape of heterocyclic compounds for autoimmune diseases. Int. J. Patent Law, 17(3), 213–240.

Drugs Protected by US Patent 7,771,707

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016		RX	Yes	No			Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-002	Apr 26, 2016		RX	Yes	No			Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-003	Apr 26, 2016		RX	Yes	No			Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016		RX	Yes	No			Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-005	Apr 26, 2016		RX	Yes	Yes			Y

International Family Members for US Patent 7,771,707

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003247876
Canada	2491572
Canada	2569958
Canada	2916869
Cyprus	1119831